Compare Cytokinetics Inc (CYTK) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Under Armour Inc Class A — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Under Armour Inc Class A trades at $6.61 (market cap $2.79B). The key difference: Cytokinetics Inc is far larger — about 4× Under Armour Inc Class A's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| CYTK | UAA | |
|---|---|---|
Market Cap | $11.12B | $2.79B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $8.14 |
52-Week Low | $33.23 | $4.17 |
Enterprise Value | $11.59B | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Under Armour (UAA) trades at $6.75, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Fundamentally, the company reported a net loss of $201.27 million in 2025 despite beating EPS expectations in two recent quarters, with revenue declining to $5.16 billion. Analyst sentiment is cautious with a consensus price target of $5.96, below the current price, and news highlights ongoing challenges in North America offset by international growth.
The outlook remains challenging with weak guidance for FY2027 and margin pressure, though international expansion and a recent Dodge collaboration offer potential catalysts. Key risks include persistent North American weakness, rising costs, and high debt levels. Investors face a stock with negative profitability metrics trading above analyst targets, suggesting limited near-term upside absent a significant operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
